In Brief: Glaxo Wellcome's Retrovir
Executive Summary
Glaxo Wellcome's Retrovir: New strengths of AZT would enable harmonization of Retrovir and Glaxo's Epivir dosing schedules: Retrovir is currently labeled for administration three times daily, while Epivir is dosed twice daily. AZT in a 300 mg tablet became "approvable" at FDA on Dec. 19; a 200 mg AZT tablet was approved the same day but is not yet marketed. Retrovir regimens typically total 500-600 mg per day. Retrovir has been available in 100 mg capsules and syrup...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth